Breakthrough in Non-Hormonal Relief for Menopausal Symptoms
Elinzanetant, a non-hormonal pill developed by Bayer, has significantly reduced menopausal hot flashes and night sweats in a late-stage trial. The study reported a 73% reduction in symptoms by week 12, compared to 47% in the placebo group. The drug also showed improvements in sleep disturbances and quality of life without adverse effects on the liver or bone density.
Elinzanetant, a non-hormonal medication developed by Bayer, has shown promising results in minimizing menopausal symptoms, according to a study published in JAMA Internal Medicine. The trial, involving over 600 postmenopausal women, revealed a remarkable reduction in vasomotor symptoms such as hot flashes and night sweats.
By the 12th week of the trial, participants taking elinzanetant reported a 73% decrease in these symptoms, significantly higher than the 47% reduction seen in the placebo group. The drug continued to demonstrate effectiveness as participants reported an average of 1.4 severe symptoms daily by week 50.
The findings suggest that elinzanetant may soon become a vital non-hormonal treatment for menopausal symptoms, offering long-term relief without impacting liver or bone health. The drug is already approved for use in the UK and Canada and is currently under review by the U.S. Food and Drug Administration.
(With inputs from agencies.)
Google News